Emzor Pharmaceutical Industries Limited, one of Nigeria’s dominant domestic drugmakers, has successfully extended its debt maturity profile, tapping local capital markets to fund the final stretch of a pioneering industrial project that promises to transform regional drug supply chains.
The Lagos-based manufacturer closed the remaining 28% funding gap for Nigeria’s first active pharmaceutical ingredient (API) manufacturing plant after restructuring its balance sheet.
Long-term money, anchored by a recent NGN26.7 billion ($17.6 million) bond issuance, has been deployed to refinance volatile short-term loans and insulate the company from immediate liquidity shocks. Management expects the anti-malaria API facility to wrap up construction by Q4 2026, positioning it to pad corporate earnings starting in 2027.
The corporate pivot comes at a critical juncture for Nigerian manufacturers navigating severe macroeconomic headwinds, foreign exchange volatility, and escalating borrowing costs.
Top-Line Surge Masked by Sticky Costs
Emzor’s financial performance highlights the dual realities of operating in Africa’s most populous nation: robust top-line expansion fueled by nominal price adjustments, alongside tightening credit metrics under the weight of high interest rates.
Revenue surged 31.2% to NGN66.9 billion in the twelve months through December 31, 2025, bringing its five-year compound annual growth rate (CAGR) to a healthy 17.5%. The performance was driven by a combination of inflation-linked price hikes and a gradual recovery in product volumes.
Efficiencies from cost-containment measures and an improved sales mix lifted the company’s EBITDA margin to 22.7% in 2025, expanding further to 24.1% during the first four months of 2026.
The Credit View: Liquidity vs. Operational Cash Drag
While structural leverage improved significantly in 2025—with the net debt-to-EBITDA ratio retreating to 2.5x from 4.7x the prior year—more recent data hints at emerging pressure points. Gross debt ticked up to NGN41.9 billion by April 2026, softening the leverage metric back to 2.8x.
More pressing for GCR credit analysts is a sharp contraction in operating cash flow (OCF) coverage of gross debt, which plummeted from 23.9% at year-end 2025 to just 1.3% in the four months to April 2026. The drop-off was driven by an aggressive inventory build-up, creating a temporary working capital bottleneck.
Concurrently, a higher interest rate environment cut EBITDA interest coverage more than in half, moving from 5.4x in 2024 to 2.2x by early 2026.
Despite these short-term operational drags, Emzor maintains a highly comfortable liquidity cushion. Its sources-to-uses ratio stands at 1.5x through December 2026 and 1.3x through late 2027, supported by net bond proceeds and NGN7.0 billion in committed, unused bank lines.
Looking Ahead
Emzor’s long-term commercial viability is anchored by extensive distribution networks, including 200 regional distributors and over 150 institutional off-takers across the private sector, state governments, and international non-governmental organizations (NGOs).
While continuous rolling of short-term working capital facilities will keep gross debt levels elevated, successful commissioning of the API plant next year is expected to catalyze volume growth, strengthen margins, and solidify its defensive market share.
 Follow the MoneyCentral Nigeria channel on WhatsApp: Click here!
